Jefferies Financial Group Cuts Replimune Group (NASDAQ:REPL) Price Target to $6.00

Replimune Group (NASDAQ:REPL - Get Free Report) had its price objective decreased by analysts at Jefferies Financial Group from $31.00 to $6.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm presently has a "buy" rating on the stock. Jefferies Financial Group's price target would indicate a potential upside of 90.48% from the stock's current price.

REPL has been the topic of several other reports. HC Wainwright restated a "buy" rating and set a $22.00 price target on shares of Replimune Group in a report on Thursday, July 3rd. JPMorgan Chase & Co. restated a "neutral" rating and set a $9.00 price target (down from $19.00) on shares of Replimune Group in a report on Tuesday. Piper Sandler cut shares of Replimune Group from an "overweight" rating to a "neutral" rating and set a $3.00 price target on the stock. in a report on Tuesday. Wedbush reaffirmed a "neutral" rating and issued a $4.00 price objective (down previously from $19.00) on shares of Replimune Group in a research note on Tuesday. Finally, Cantor Fitzgerald started coverage on shares of Replimune Group in a research note on Friday, June 20th. They issued an "overweight" rating for the company. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $7.67.

Replimune Group Stock Performance

Shares of NASDAQ REPL traded up $0.05 during mid-day trading on Tuesday, reaching $3.15. 5,553,450 shares of the company traded hands, compared to its average volume of 9,075,726. Replimune Group has a fifty-two week low of $2.68 and a fifty-two week high of $17.00. The company has a debt-to-equity ratio of 0.17, a current ratio of 7.95 and a quick ratio of 7.95. The stock has a fifty day simple moving average of $9.37 and a 200-day simple moving average of $10.30.

Replimune Group (NASDAQ:REPL - Get Free Report) last posted its quarterly earnings results on Thursday, May 22nd. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.07). During the same period in the previous year, the business posted ($0.25) EPS. Analysts anticipate that Replimune Group will post -2.97 EPS for the current fiscal year.

Insider Transactions at Replimune Group

In other news, insider Konstantinos Xynos sold 7,952 shares of Replimune Group stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $8.06, for a total value of $64,093.12. Following the completion of the transaction, the insider owned 146,933 shares of the company's stock, valued at $1,184,279.98. This trade represents a 5.13% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Philip Astley-Sparke sold 32,279 shares of Replimune Group stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $8.06, for a total transaction of $260,168.74. Following the sale, the director directly owned 1,405,071 shares of the company's stock, valued at $11,324,872.26. The trade was a 2.25% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 74,907 shares of company stock worth $603,655. 8.80% of the stock is owned by insiders.

Institutional Trading of Replimune Group

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Price T Rowe Associates Inc. MD boosted its position in Replimune Group by 11.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 10,962,883 shares of the company's stock valued at $132,761,000 after buying an additional 1,083,633 shares in the last quarter. Redmile Group LLC boosted its position in Replimune Group by 2.6% in the fourth quarter. Redmile Group LLC now owns 4,905,527 shares of the company's stock valued at $59,406,000 after buying an additional 124,344 shares in the last quarter. Vanguard Group Inc. boosted its position in Replimune Group by 6.6% in the first quarter. Vanguard Group Inc. now owns 3,833,033 shares of the company's stock valued at $37,372,000 after buying an additional 237,185 shares in the last quarter. Tang Capital Management LLC boosted its position in Replimune Group by 125.0% in the fourth quarter. Tang Capital Management LLC now owns 2,700,000 shares of the company's stock valued at $32,697,000 after buying an additional 1,500,000 shares in the last quarter. Finally, RTW Investments LP boosted its position in Replimune Group by 82.1% in the fourth quarter. RTW Investments LP now owns 2,065,010 shares of the company's stock valued at $25,007,000 after buying an additional 931,223 shares in the last quarter. Institutional investors and hedge funds own 92.53% of the company's stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.